Rye Brook Capital LLC sold all 24,270 shares of iShares Biotechnology ETF (IBB), totaling $3.50 million, as per SEC filing. Post-trade, the fund holds no IBB shares. The top holdings now include QQQ, U-UN.TO, SMH, KWEB, and NXE. Shares of IBB were priced at $175.85 on January 26, 2026, with a 1-year return of 28.42%.

Rye Brook Capital’s exit from IBB signifies a strategic shift in sector allocation. The biotech sector saw a strong 2025, driven by M&A activity. IBB surged 28% in a year. Exiting during a rally may indicate profit-taking or skepticism about valuations. IBB suits growth investors anticipating M&A momentum but not risk-averse ones.

Rye Brook Capital’s trade signals a significant change in investment strategy. IBB’s performance reflects the biotech sector’s volatility. The ETF offers exposure to the biotech industry’s growth and innovation but is not suitable for conservative investors due to its risk and volatility. Story Continues

The Motley Fool highlights stocks that have shown significant growth in the past, like Nvidia, Apple, and Netflix. They issue “Double Down” alerts for promising companies to invest in. The article encourages investors to seize opportunities before they’re missed. These recommendations are available through Stock Advisor.

Read more at Yahoo Finance: This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF